Mankind Pharma gets DRDO nod to make and market 2-DG

The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.

64
DRDO

Last Updated on July 11, 2021 by The Health Master

Mankind Pharma said it has received the licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of C-19. 2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior.

The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy’s Laboratories, Mankind Pharma said in a statement.

The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.

DCGI CDSCO

The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe C-19 patients, Mankind Pharma said.

The drug is found to help the hospitalised C-19 patients recover faster and is also known to reduce the supplemental oxygen dependency among the C-19 patients, it added.

‘Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic,’ the company said.

40 Pharma Firms showed interest in anti Covid drug: DRDO

DRDO develops C-19 Antibody detection kit

CDSCO asks Philips India to discontinue these Ventilators

IPCA Lab gets CDSCO nod to conduct Phase-III study of HCQ

Mankind gets CDSCO nod for phase-I trial of Anti Diabetic drug

IPC and CDSCO meet to outline plan for designing Pharmacovigilance cell

All Legislation of India (for Pharma and Health professionals)

Latest Notifications: General (Pharmaceuticals)

Starch powder sold as Black Fungus medicine: Scam busted

Fake Favipiravir racket busted: FIR lodged

Delhi High Court set up IPD for Pharma Industry

ER for D Pharmacy is a step in right direction: Pharmacy…

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner